RxDoctor Payments Data

Pedro Alcedo Andrade, MD

Hospitalist · Washington, DCNPI 1770013211

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $39,652 of the $48,440 with a category attached, or 81.9%. Sanofi accounts for 96.6% of it on its own, with 11 other manufacturers making up the rest. Among hospitalist clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$48,440in general payments, 2019–2025

Across 59 payments — averaging $821.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$47K
  • Bayer$886
  • Inari Medical, Inc.$145
  • Jazz Pharmaceuticals Inc.$143
  • Novo Nordisk$138
  • AstraZeneca$122
  • plus $218 from 6 others
$27,975in research payments, 2019–2025

Across 1 payment — averaging $27,975 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Grifols Therapeutics LLC$28K

What the payments were for

  • Consulting fees$3,7788%
  • Speaking & faculty fees$39,65282%
  • Travel & lodging$3,0116%
  • Food & beverage$2,0004%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,440 in reported general payments places this provider in the 95th percentile of 101 hospitalist providers in District of Columbia.

See all hospitalist providers in District of Columbia

Medicare billing

Part B allowed, 2024
$35,948
Medicare patients
157
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$53,828
XareltoRivaroxaban20$28,353
Cyclosporine ModifiedCyclosporine, Modified21$4,212
Tranexamic Acid12$602
Oxycodone Hcl15$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$53,82848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 hospitalist providers in District of Columbia.

Other hospitalist in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →